VC Playbook: Finding Early-Stage Financing When Money Is Scarce

 
• By David Wild
  
Generate a summary of this article
Listen to this article
Beta

Early-stage companies need to be more flexible on the financing terms they are willing to accept and in finding ways to gather evidence to support the impact of their products or services.

Early Stage Companies Need To Change Their Approach In A More Conservative Funding Environment • Source: Shutterstock

The pace of decline in biopharma venture capital investment over the past year has been striking: after an impressive first quarter in 2022, when biopharma companies raised $11.9bn, the amount of VC funding contracted to $5.7bn by Q4, well below all four quarterly totals in the prior two years. (Also see "Finance Watch: Founder-Friendly Curie.Bio Launches With $520m To Seed, Support New Companies" - Scrip, 16 February, 2023.)

There’s no indication things are improving, with panelists at the Biotechnology Innovation Organization’s CEO & Investor Conference saying they see...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

SpotifyApple PodcastsWebsite

More from VC Playbook

IV-Growth (Free-1): Jump-Start Your Exercise With This Mindset Reset

 
• By Nabil

A positive mindset can boost exercise motivation. Learn how mental shifts help you start—and stick with—a healthier fitness routine.

Podcast: Improving Communication – The Relationship Between Biotech And Pharma

 
• By David Wild

Ali Pashazadeh, CEO, chair and founder of Treehill Partners discusses the need for increased communication between biotech and biopharma. 

Lucie Ellis-Taitt Test Article

 
• By Lucie Ellis-Taitt

Exec summary testing space - June 2024.

Investing Is A People Business, Says LifeArc’s Clare Terlouw

 
• By Ashley Yeo

Success in life sciences venture funding requires drive and speed, says In Vivo Rising Leader, Clare Terlouw. But there is more to it than that.  

More from Growth

2023-2024 Global Biopharma R&D Productivity And Growth Ranking

 
• By Markus Thunecke, Erika Kuchen, and Alexander Wallroth

The overall R&D productivity of the 30 largest public biopharma companies has increased despite a challenging global environment for investment and growth. Will hype cycles impact this picture in coming years?

podcast

Podcast: Thermo Fisher’s Meron Mathias On Why Environmental Sustainability Must Be A Top Priority

 
• By Ashley Yeo

Meron Mathias is vice president of CSR and sustainability at Thermo Fisher, whose specialty diagnostics division makes it the fifth leading player by revenues in the global IVD industry. In this podcast, she reflects on Thermo Fisher’s early commitment to ESG and sustainability reporting, its Scope 1, 2 and 3 targets and how regulation is moving industry towards a mandatory disclosure landscape.

Podcast: Thermo Fisher’s Meron Mathias On Why Environmental Sustainability Must Be A Top Priority

 
• By Ashley Yeo

Meron Mathias is vice president of CSR and sustainability at Thermo Fisher, whose specialty diagnostics division makes it the fifth leading player by revenues in the global IVD industry. In this podcast, she reflects on Thermo Fisher’s early commitment to ESG and sustainability reporting, its Scope 1, 2 and 3 targets and how regulation is moving industry towards a mandatory disclosure landscape.